What is Lee's Pharmaceutical Holdings FCF Yield %?
Lee's Pharmaceutical HoldingsFRA:L1PA 72 FCF Yield % is 15.79 as of Jul. 03, 2026, which is 1028% above its 10-year median of 1.40. GuruFocus rates FRA:L1PA with a GF Score™ of 72/100 and a GF Value™ of €0.17. The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Lee's Pharmaceutical Holdings ranks better than 94.14% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lee's Pharmaceutical Holdings FCF Yield % Related Terms
Lee's Pharmaceutical Holdings FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (FRA:L1PA) has a FCF Yield % of 15.79 as of Jul. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 1028% above median its historical median of 1.40. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #59 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is Lee's Pharmaceutical Holdings' FCF Yield % too high?
Lee's Pharmaceutical Holdings' current FCF Yield % of 15.79 is 1028% above median its 10-year median of 1.40. The Drug Manufacturers industry median FCF Yield % is 0.67. Lee's Pharmaceutical Holdings' value of 15.79 is 2274.4% above this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #59 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #59 out of 1006 companies for FCF Yield %. This places Lee's Pharmaceutical Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Lee's Pharmaceutical Holdings' value of 15.79 is 2274.4% above this benchmark. While the company's 10-year median is 1.40 vs. the industry median of 0.67, Lee's Pharmaceutical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current FCF Yield % of 15.79 is 2274.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current FCF Yield % is 15.79, which is 1028% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current FCF Yield % of 15.79. The stock's GF Value™ is €0.17, compared to a current price of €0.11 — trading 37.1% below its estimated fair value. The current FCF Yield % is 15.79, which is 1028% above median its 10-year median of 1.40 and 2274.4% above the Drug Manufacturers industry median of 0.67. Lee's Pharmaceutical Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current FCF Yield % is 15.79 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of €0.11 is trading 37.1% below its estimated GF Value™ of €0.17.
Key valuation signals for FRA:L1PA:
FCF Yield %: 15.79 (1028% above median its 10-year median of 1.40)
GF Value™: €0.17 vs. price of €0.11 (37.1% below fair value)
Industry Position: 2274.4% above the Drug Manufacturers median (#59 of 1006)
No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
72GF Score
Get the complete analysis for FRA:L1PA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L1PA has been successfully added to your 
